| 1 |
Uncharacterized liver damage leading to hepatocellular carcinoma |
BY-SA |
|
| 32 |
Inhibition of iNOS, hepatotoxicity, and regenerative proliferation leading to liver tumors |
BY-SA |
|
| 240 |
DNA Adducts Leading to Liver Hemangiosarcoma |
BY-SA |
|
| 273 |
Mitochondrial complex inhibition leading to liver injury |
BY-SA |
|
| 278 |
IKK complex inhibition leading to liver injury |
BY-SA |
|
| 285 |
Inhibition of N-linked glycosylation leads to liver injury |
BY-SA |
|
| 454 |
PM2.5-related AOP frameworks on liver diseases |
BY-SA |
|
| 494 |
AhR activation leading to liver fibrosis |
BY-SA |
|
| 514 |
PLK1 Activation leading to hepatocyte apoptosis-associate liver injury via autophagy-mediated excessive COX6A1 degradation and impaired function of mitochondrial respiratory chain complex IV |
BY-SA |
|
| 517 |
Pregnane X Receptor (PXR) activation leads to liver steatosis |
BY-SA |
|
| 518 |
Liver X Receptor (LXR) activation leads to liver steatosis |
BY-SA |
|
| 529 |
Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis |
BY-SA |
|
| 537 |
Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver |
BY-SA |
|
| 591 |
DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration |
BY-SA |
|
| 638 |
Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis |
BY-SA |
|
| 642 |
Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation |
BY-SA |
|
